
LeMaitre Vascular (LMAT) Stock Forecast & Price Target
LeMaitre Vascular (LMAT) Analyst Ratings
Bulls say
LeMaitre Vascular is poised for growth with strong financials and a positive outlook. With a 10% organic revenue increase and plans for international expansion, the company's profitability has improved and they have seen success in M&A with their recent acquisition of Artegraft. Despite risks in compliance and manufacturing, LeMaitre has a record of successful financial performance and a continued focus on growth and investment opportunities.
Bears say
LeMaitre Vascular is expected to see strong performance and growth in international markets due to its recent investments and expansion in those regions, while also benefiting from a favorable pricing environment and increased sales representatives. However, the company's declining sales representatives and lower-than-expected unit volume growth in the first quarter raise concerns about its ability to sustain growth in the long term and highlight potential difficulties in achieving its ambitious sales representative target for 2026. This, along with pressure on pricing moving forward, suggests a cautious outlook for the company's overall revenue and earnings growth.
This aggregate rating is based on analysts' research of LeMaitre Vascular and is not a guaranteed prediction by Public.com or investment advice.
LeMaitre Vascular (LMAT) Analyst Forecast & Price Prediction
Start investing in LeMaitre Vascular (LMAT)
Order type
Buy in
Order amount
Est. shares
0 shares